| With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor | Frank Vinluan | 08/12/20 | New York |
| Court Rules More Trial Data Must Be Posted On ClinicalTrials.gov | Brenda Sandburg | 03/04/20 | National |
| FDA Flags Risk of Infection, Kidney Damage for Sarepta Duchenne Drugs | Frank Vinluan | 01/22/20 | Boston |
| Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More | Frank Vinluan | 12/13/19 | National |
| In an About-Face, FDA Approves Second Sarepta Muscular Dystrophy Drug | Sarah de Crescenzo | 12/13/19 | Boston |
| Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More | Frank Vinluan | 08/23/19 | National |
| FDA Rejects Sarepta’s Second Duchenne Drug, Citing Safety Concerns | Ben Fidler | 08/19/19 | Boston |
| Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More | Frank Vinluan | 08/02/19 | National |
| Duchenne Advocates Start Casimir, Aiming to Capture Missing Data | Ben Fidler | 07/26/19 | Boston |
| With Its First Human Data, Solid Slips in Duchenne Gene Therapy Race | Ben Fidler | 02/07/19 | Boston |
| Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More | Alex Lash | 12/21/18 | National |
| 15 for ’19: Key Clinical Data to Watch for Next Year (Part 1) | Ben Fidler | 12/17/18 | National |
| Sarepta Touts New Data and a “Signal” With Duchenne Gene Therapy | Ben Fidler | 10/03/18 | Boston |
| Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure | Frank Vinluan | 06/27/18 | Boston |
| Sarepta’s Data Are First in Rush for Duchenne Gene Therapy | Ben Fidler | 06/19/18 | Boston |
| Bio Roundup: IDO Fallout, Express Scripts Dumps Amgen, Isaly Out & More | Ben Fidler | 05/04/18 | National |
| Life Sci Veteran Garabedian Talks Up Biotech Accelerator in Texas | David Holley | 04/23/18 | Texas |
| Solid Discloses Duchenne Problems in IPO & Raises Rival’s Hackles | Ben Fidler | 01/25/18 | Boston |
| Bio Roundup: Migraine Data, Cancer Drug Combos, Azar Hearing & More | Frank Vinluan | 12/01/17 | National |
| Ed Kaye on Sarepta’s Duchenne Quest, Rising to CEO & His New Startup | Ben Fidler | 11/20/17 | Boston |
| With $40M for Exonics, Duchenne’s Gene Therapy, CRISPR Race Heats Up | Ben Fidler | 11/08/17 | Boston |
| FDA Panel Pans PTC’s Audacious Plan to Force Vote on Duchenne Drug | Ben Fidler | 09/28/17 | New York |
| Bio Roundup: GOP Drama, Immunotherapy Setbacks, Pharma Revamps | Ben Fidler | 07/28/17 | National |
| Woodcock: New Approvals Show FDA Is Adapting to Precision Medicine | Frank Vinluan | 05/30/17 | National |
| Ex-Sarepta CEO Garabedian Returns to Run Bio Accelerator Xontogeny | Frank Vinluan | 05/18/17 | Boston |
| Analysts Expect Payer Pushback as PTC Sets $35K Price For Duchenne Drug | Frank Vinluan | 05/08/17 | New York |
| After Sarepta’s Surprising FDA Nod, CEO Kaye Plans to Resign | Ben Fidler | 04/28/17 | Boston |
| Duchenne, SMA, and the Rise of Patient Power at “What’s Hot” on May 11 | Ben Fidler | 04/27/17 | Boston |
| Next Stop on Father’s Duchenne Quest: Wall Street? Solid Raises $50M | Ben Fidler | 03/30/17 | Boston |
| After a Clinical Trial Death, FDA OKs New Tests of Akashi’s Duchenne Drug | Ben Fidler | 03/22/17 | Boston |
